Lumipulse^® G ADxPLORER^® VAMP2

Vesicle-associated membrane protein 2 (VAMP-2) is a surrogate cerebrospinal fluid (CSF) marker of episodic memory in adults with Down syndrome and a promising marker for synapse degeneration in Dementia with Lewy Bodies^1,2. Synapse loss is an early event that precedes neuronal death and symptom onset and is considered the best neuropathological correlate of cognitive decline in Alzheimer’s disease (AD). VAMP-2 has emerged as a promising CSF biomarker associated with AD-related synaptic degeneration and may have potential as an early target engagement marker reflecting reduced synaptic damage ³. However, its clinical utility remains to be further established ^4,5. VAMP-2 is also among the synaptic proteins included in patent application WO2019175379 A1 (Markers of synaptopathy in neurodegenerative disease). 

The Lumipulse® G ADxPLORER® VAMP2 assay was developed using a proprietary VAMP-2 mouse monoclonal antibody ADx414 (90586) in conjunction with an alkaline phosphatase-conjugated Fab fragment derived from the recombinant ADx413 mAb (90585). The assay is calibrated with an acetylated VAMP-2 synthetic peptide.
 

References:

1. Lleó et al. VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome. Alzheimers Res Ther. 2021 Jun 28;13(1):119.
2. González et al. Evaluation of cerebrospinal fluid levels of VAMP-2 and SNAP-25 in a dementia with Lewy bodies clinical cohort stratified by Alzheimer's pathophysiological biomarkers. Alzheimers Res Ther. 2025 Feb 24;17(1):51.
3. Goossens et al. Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer's disease continuum. Alzheimers Res Ther. 2023 Oct 28;15(1):186.
4. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002 Oct 25;298(5594):789-91.
5. Cline et al. (2025). Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease. Journal of Prevention of Alzheimer's Disease. 12(4), 100082.

Lumipulse is a registered trademark of Fujirebio Inc.
ADxPLORER is a registered trademark of Fujirebio Europe NV.